Current Report Filing (8-k)
June 14 2019 - 9:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 14, 2019
Sage Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-36544
|
|
27-4486580
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
215 First Street
Cambridge, MA
|
|
02142
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(617) 299-8380
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.0001 per share
|
|
SAGE
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§ 240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On June 14, 2019, Sage Therapeutics, Inc. (the Company) issued a press release titled Sage Therapeutics Announces U.S. Drug Enforcement
Administration Scheduling of ZULRESSO
(brexanolone) Injection. A copy of the press release is attached as Exhibit 99.1 to this
Form 8-K and
incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 14, 2019
|
|
|
|
SAGE THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Anne Marie Cook
|
|
|
|
|
|
|
Anne Marie Cook
|
|
|
|
|
|
|
Senior Vice President, General Counsel
|
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024